GYPC and Lassa fever: To expand the repertoire of available anti-GPC mAbs, we used LIV GPC-I53-50A as a bait for antigen-specific B cell sorting of convalescent serum from patient 1102370, a member of the Lassa fever survivor cohort at the Kenema Government Hospital.19